MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status:
Recruiting
Trial end date:
2037-10-01
Target enrollment:
Participant gender:
Summary
Phase I study to establish safety and feasibility of intraperitoneally administered
lentiviral transduced MOv19-BBz CAR T cells with or without cyclophosphamide + fludarabine as
lymphodepleting chemotherapy
Phase:
Phase 1
Details
Lead Sponsor:
University of Pennsylvania
Treatments:
Cyclophosphamide Fludarabine Folic Acid Vitamin B Complex